Holoclara develops immunotherapy treatments for autoimmune disorders using nematode-derived molecules. The company aims to provide relief for millions suffering from debilitating diseases by targeting the underlying immune responses associated with these conditions.
Funding
$21.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Autoimmune disorders affect millions, causing debilitating symptoms due to dysregulated immune responses. Current treatments often manage symptoms but do not address the underlying cause of the immune dysfunction.
Solution
Holoclara is developing novel immunotherapies for autoimmune diseases based on molecules derived from nematodes. These therapies aim to re-balance the immune system, addressing the root cause of autoimmune disorders rather than merely suppressing symptoms. By targeting specific immune pathways, Holoclara seeks to provide long-lasting relief and improve the quality of life for individuals suffering from these conditions. The nematode-derived molecules are designed to modulate the immune response, promoting tolerance and preventing the body from attacking its own tissues.
Target Audience
The primary target audience includes individuals suffering from various autoimmune disorders and the healthcare providers who treat them.
Features
- Immunotherapies based on nematode-derived molecules
- Targeted modulation of specific immune pathways
- Designed to promote immune tolerance
- Aims to address the underlying cause of autoimmune disorders